Navigation Links
American Pacific Reports Fiscal 2013 Results; Provides Outlook For Fiscal 2014
Date:12/12/2013

(838)Deferred Tax Asset Valuation Allowance

-

10,420

-

10,420As Reported

$ 10,849

$ 14,178

$ 23,133

$ 20,332Diluted Earnings per Share from Continuing Operations:As adjusted

$
.32

$
.52

$
3.08

$
.32Remediation Charge

-

(0.05)

-

(0.05)Other Operating Gains

-

0.13

-

0.13Loss on Debt Extinguishment

-

(0.11)

(0.22)

(0.11)Deferred Tax Asset Valuation Allowance

-

1.34

-

1.36As Reported

$
.32

$
.83

$
2.86

$
2.65CONSOLIDATED RESULTS OF OPERATIONSRevenuesFiscal 2013 revenues increased 16% to $215.1 million as compared to $185.6 million for Fiscal 2012, reflecting revenue increases from each of our operating segments.  Fiscal 2013 fourth quarter revenues increased 19% to $59.2 million from $49.6 million for the Fiscal 2012 fourth quarter. See further discussion below under Segment Highlights. 

Cost of Revenues and Gross Profit – Fiscal 2013 cost of revenues was $128.1 million compared to $119.5 million for Fiscal 2012. The Fiscal 2013 consolidated gross margin was 40% compared to 36% for Fiscal 2012.
Fiscal 2013 fourth quarter cost of revenues was $28.8 million compared to $30.2 million for the Fiscal 2012 fourth quarter. The Fiscal 2013 fourth quarter consolidated gross margin was 51% compared to 39% for the Fiscal 2012 fourth quarter. On a consolidated level, one of the most significant factors that affects, and should continue to affect, the comparison of our consolidated gross profit and gross margin from period to period is the change in revenue mix among our segments. The revenue contribution by each of our segments is indicated in the following table. Quarter Ended September 30, 

 Yea
'/>"/>

SOURCE American Pacific Corporation
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26

Related medicine technology :

1. American Academy of Family Physicians Foundation Launches Cities for Life
2. Interim results of VITOBA™ (VImpaT® added to One Baseline AED) Study Presented at the 64th Annual Meeting of the American Academy of Neurology
3. Elsevier Selected as New Publisher of The American Journal of Geriatric Psychiatry
4. Shire to Present Scientific Data Across Range of Psychiatric Disorders at American Psychiatric Association Annual Meeting May 5-9
5. Data Presented at the American Psychiatric Association Annual Meeting Supports Gender-Specific Dosing of Intermezzo® (zolpidem tartrate) Sublingual Tablets CIV
6. New Data to be Presented at the Annual American Thoracic Society International Conference Demonstrates Depth of Boehringer Ingelheim Respiratory Research Pipeline
7. NVA237 Phase III GLOW2 Data at American Thoracic Society (ATS) International Conference and Phase II Clinical Trial Update
8. Pharmacyclics Announces Oral Presentations and Clinical Update of Ibrutinib (PCI-32765) at the 2012 Annual Meeting of the American Society of Clinical Oncology
9. Purdue Pharma L.P. To Present Analysis Of Butrans® (buprenorphine) Transdermal System CIII Clinical Data At American Pain Society Annual Meeting
10. Percutaneous Tibial Nerve Stimulation Included in the American Urological Associations Overactive Bladder Clinical Treatment Guidelines
11. Lilly Diabetes Presents Phase II Blood Pressure and Heart Rate Data on Investigational GLP-1 Analog Candidate, Dulaglutide, in Patients with Type 2 Diabetes at the 27th American Society of Hypertension Scientific Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/22/2014)... York , September 22, 2014 ... (MRI) market has been recently added to Transparency Market ... (MRI) Market: Global Market Analysis, Size, Share & Forecast ... MRI market, which valued US$ 3.9 billion in 2011, ... 2011 to 2017(the forecast period of the report), and ...
(Date:9/22/2014)... 2014  Elusys Therapeutics, Inc. (Elusys), a biopharmaceutical ... today announced it has completed three phase 3 ... Obiltoxaximab is an anti-toxin in development for the ... studies support the safety and tolerability of the ... therapeutic dose. The conclusion of these studies marks ...
(Date:9/22/2014)... -- Persistence Market Research ( http://www.persistencemarketresearch.com/ ) ... Ophthalmic Devices: Asia to Witness ... at USD 29,171.5 million in 2014 and is expected ... to 2020, to reach an estimated value of USD ... Market Study on Ophthalmic Devices:  Asia  to ...
Breaking Medicine Technology:Global Magnetic Resonance Imaging (MRI) Market Worth US $4.8 Billion by 2017: Transparency Market Research 2Global Magnetic Resonance Imaging (MRI) Market Worth US $4.8 Billion by 2017: Transparency Market Research 3Global Magnetic Resonance Imaging (MRI) Market Worth US $4.8 Billion by 2017: Transparency Market Research 4Elusys Announces Results From Three Phase 3 Safety Studies Of Its Anthrax Anti-Toxin, Obiltoxaximab (ETI-204), In Adult Volunteers And Completion Of Its Phase 3 Clinical Development Program 2Elusys Announces Results From Three Phase 3 Safety Studies Of Its Anthrax Anti-Toxin, Obiltoxaximab (ETI-204), In Adult Volunteers And Completion Of Its Phase 3 Clinical Development Program 3Elusys Announces Results From Three Phase 3 Safety Studies Of Its Anthrax Anti-Toxin, Obiltoxaximab (ETI-204), In Adult Volunteers And Completion Of Its Phase 3 Clinical Development Program 4Elusys Announces Results From Three Phase 3 Safety Studies Of Its Anthrax Anti-Toxin, Obiltoxaximab (ETI-204), In Adult Volunteers And Completion Of Its Phase 3 Clinical Development Program 5Elusys Announces Results From Three Phase 3 Safety Studies Of Its Anthrax Anti-Toxin, Obiltoxaximab (ETI-204), In Adult Volunteers And Completion Of Its Phase 3 Clinical Development Program 6Global Ophthalmic Devices Market will Reach $2,685.1 Million in 2020: Persistence Market Research 2Global Ophthalmic Devices Market will Reach $2,685.1 Million in 2020: Persistence Market Research 3Global Ophthalmic Devices Market will Reach $2,685.1 Million in 2020: Persistence Market Research 4Global Ophthalmic Devices Market will Reach $2,685.1 Million in 2020: Persistence Market Research 5
(Date:9/22/2014)... MONDAY, Sept. 22, 2014 (HealthDay News) -- Metformin, a ... risk of low levels of thyroid-stimulating hormone (TSH) among ... The researchers cautioned that low TSH levels may ... a cause-and-effect link was not established in this study. ... thyroid (hypothyroidism), there were 495 incidences of low levels ...
(Date:9/22/2014)... The “ Ztylus ” was featured on NewsWatch ... reviews and features the latest technology gadgets and services available ... expert, conducted the review and shared with viewers how it’s ... gives users four lens options for their camera. , The ... Tech Report, which reviews and features the latest technology gadgets ...
(Date:9/22/2014)... 2014 “The Race is On!” for the ... Sunday, October 12, 2014 as it moves to its new ... As the signature fundraising and awareness event for Susan G. ... Phoenix Race for the Cure provides supporters of all ages ... and even sleeping in. , “Moving the Race to ...
(Date:9/22/2014)... perspiration these symptoms are a few of the ... heart rate and plays a crucial role in its ... Aviv University points to an additional complication caused by ... Mammalian Genome , was conducted by Prof. Karen ... of Human Molecular Genetics and Biochemistry at TAU,s Sackler ...
(Date:9/22/2014)... A study led by University of North Carolina at ... the accurate diagnosis of people who are experiencing the ... delusions that define the development of severe mental disorders ... early adulthood and affects about 1 in every 100 ... person can be a life compromised, and the burden ...
Breaking Medicine News(10 mins):Health News:Diabetes Drug Metformin May Affect Thyroid in Some Patients 2Health News:NewsWatch Recently Featured the Phone Case “Ztylus” on National Television 2Health News:22nd Annual Susan G. Komen Phoenix Race for the Cure® 2014 Moves to Downtown Phoenix 2Health News:22nd Annual Susan G. Komen Phoenix Race for the Cure® 2014 Moves to Downtown Phoenix 3Health News:Lack of thyroid hormone blocks hearing development 2Health News:Blood test may help determine who is at risk for psychosis 2
... HOUSTON - A vaccine that turns the immune system ... drives the most aggressive form of glioblastoma multiforme improved ... researchers at Duke University and The University of Texas ... Journal of Clinical Oncology . Eighteen newly diagnosed ...
... Oct. 6, 2010 A set of proteins found in ... to diagnose Alzheimer,s disease, researchers at UT Southwestern Medical Center ... An analysis of the proteins, plus a clinical exam, proved ... accurate in ruling it out in people without the disease, ...
... Reinberg HealthDay Reporter , TUESDAY, Oct. 5 (HealthDay ... young adults admit they are binge drinkers, health officials said ... as having four or more drinks for women, and five ... -- numbers that are different because men and women metabolize ...
... to a discovery by a Saint Louis University researcher, scientists ... better control cholesterol levels in blood. Led by ... at Saint Louis University and published in a recent issue ... of the United States of America, the study found that ...
... New neuroscience research by life scientists from UCLA and Australia may ... to brain injury or disease. By examining how ... way the brain first captures and encodes a situation or event ... The study is published in the Sept. 29 edition ...
... By Randy Dotinga HealthDay Reporter , ... study is the latest to suggest that testosterone may ... causing serious side effects. Researchers aren,t yet ready ... to female patients. However, the treatment does hold some ...
Cached Medicine News:Health News:Vaccine extends glioblastoma patients' survival in phase II trial 2Health News:Blood test could diagnose Alzheimer's disease, UT Southwestern researchers find 2Health News:1 in 4 U.S. Teens and Young Adults Binge Drink: CDC 2Health News:1 in 4 U.S. Teens and Young Adults Binge Drink: CDC 3Health News:Better cholesterol drugs may follow Saint Louis University researcher's breakthrough 2Health News:Neuroscience research may help patients recover from brain injury 2Health News:Testosterone Could Boost Health of Heart Failure Patients 2
... a range of Milli-Q ultrapure water ... quality requirements. Each of the five ... specifically target contaminants detrimental to particular ... and ICP-MS. The systems incorporate a ...
... Millipore has developed a range ... to match specific water quality requirements. ... systems is designed to specifically target ... as HPLC, molecular biology and ICP-MS. ...
... range of Milli-Q ultrapure water systems ... requirements. Each of the five new ... target contaminants detrimental to particular applications ... ICP-MS. The systems incorporate a high ...
... has developed a range of Milli-Q ... specific water quality requirements. Each of ... designed to specifically target contaminants detrimental ... molecular biology and ICP-MS. The systems ...
Medicine Products: